Addressing diseases of the central nervous system in an entirely new way.

Depression represents the leading cause of disability in the world, according to WHO.¹ Despite multiple drug classes and dozens of approved therapies, there is a significant unmet need for additional, novel treatments that are safe, effective, rapid acting, and well-tolerated to improve the lives of people living with major depressive disorder (MDD).

We believe that REL-1017 has the potential to treat people with MDD safely, effectively, more quickly and with greater tolerability than has previously been thought possible. We have advanced REL-1017 to Phase 3 as an adjunctive treatment for MDD while planning additional indications.

Ours is a team of experienced professionals committed to improving the lives of those living with MDD, and potentially other CNS diseases. As we advance our lead program through registration Phase 3 studies, we are expanding our team accordingly.

We are a late-stage biotech company registered and traded on the NASDAQ stock exchange under RLMD. Learn more from recent press releases and presentations.